Detection of E119V and E119I mutations in influenza a (H3N2) viruses isolated from an immunocompromised patient: Challenges in diagnosis of oseltamivir resistance

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1834-1841

  Okomo Adhiambo, Margaret ^a   Demmler Harrison, Gail J ^b   Deyde, Varough M ^a   Sheu, Tiffany G ^a   Xu, Xiyan ^a   Klimov, Alexander I ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 315675; ADAMANTANE; AMINO ACID; CYCLOSPORIN; DEXAMETHASONE; NUCLEOTIDE; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL CELL; ARTICLE; CASE REPORT; CELL CULTURE; CELL STRAIN; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; FLUORESCENCE; GENETIC VARIABILITY; HUMAN; IC 50; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA VIRUS A H3N2; MALE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; VIRUS DETECTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS PLAQUE; VIRUS PURIFICATION;

ANTIVIRAL AGENTS; CELLS, CULTURED; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; GENETIC TESTING; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; OSELTAMIVIR; POINT MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 77951214216     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01608-09     Document Type: Article

References (39)

1. Abed, Y., M. Baz, and G. Boivin. 2009. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J. Infect. Dis. 199:180-183.
2. Aoki, F. Y., G. Boivin, and N. Roberts. 2007. Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 12:603-616.
3. Barnett, J. M., A. Cadman, D. Gor, M. Dempsey, M. Walters, A. Candlin, M. Tisdale, P. J. Morley, I. J. Owens, R. J. Fenton, A. P. Lewis, E. C. J. Claas, G. F. Rimmelzwaan, R. De Groot, and A. D. M. E. Osterhaus. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:78-87.
4. Baz, M., Y. Abed, J. McDonald, and G. Boivin. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561.
5. Bright, R. A., M. J. Medina, X. Xu, G. Perez-Oronoz, T. R. Wallis, X. M. Davis, L. Povinelli, N. J. Cox, and A. I. Klimov. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181.
6. Buxton, R. C., B. Edwards, R. R. Juo, J. C. Voyta, M. Tisdale, and R. C. Bethell. 2000. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280:291-300.
7. Carr, J., J. Ives, L. Kelly, R. Lambkin, J. Oxford, D. Mendel, L. Tai, and N. Roberts. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54:79-88.
8. Colacino, J. M., W. G. Laver, and G. M. Air. 1997. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J. Infect. Dis. 176(Suppl. 1):S66-S68.
9. Colman, P. M. 2005. Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev. Anti Infect. Ther. 3:191-199.
10. Colman, P. M., J. N. Varghese, and W. G. Laver. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303: 41-44.
11. Dapat, C., Y. Suzuki, R. Saito, Y. Kyaw, Y. Y. Myint, N. Lin, H. N. Oo, K. Y. Oo, N. Win, M. Naito, G. Hasegawa, I. C. Dapat, H. Zaraket, T. Baranovich, M. Nishikawa, T. Saito, and H. Suzuki. 2010. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg. Infect. Dis. [Epub ahead of print.] doi:10.3201/eid1603.091321.
12. Deyde, V. M., M. Okomo-Adhiambo, T. G. Sheu, T. R. Wallis, A. Fry, N. Dharan, A. I. Klimov, and L. V. Gubareva. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81:16-24.
13. Deyde, V. M., X. Xu, R. A. Bright, M. Shaw, C. B. Smith, Y. Zhang, Y. Shu, L. V. Gubareva, N. J. Cox, and A. I. Klimov. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196:249-257.
14. Ferraris, O., and B. Lina. 2008. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41:13-19.
15. Freund, B., S. Gravenstein, M. Elliott, and I. Miller. 1999. Zanamivir: a review of clinical safety. Drug Saf. 21:267-281.
16. Gubareva, L. V., M. J. Robinson, R. C. Bethell, and R. G. Webster. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71: 3385-3390.
17. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
18. Gubareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
19. Hayden, F. G. 2004. Pandemic influenza: is an antiviral response realistic? Pediatr. Infect. Dis. J. 23:S262-S269.
20. Herlocher, M. L., J. Carr, J. Ives, S. Elias, R. Truscon, N. Roberts, and A. S. Monto. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111.
21. Herlocher, M. L., R. Truscon, S. Elias, H. L. Yen, N. A. Roberts, S. E. Ohmit, and A. S. Monto. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
22. Hurt, A. C., J. K. Holien, M. Parker, A. Kelso, and I. G. Barr. 2009. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83:10366-10373.
23. Ison, M. G., and F. G. Hayden. 2002. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr. Opin. Infect. Dis. 15:355-367.
24. Ison, M. G., L. V. Gubareva, R. L. Atmar, J. Treanor, and F. G. Hayden. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764.
25. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
26. Meijer, A., A. Lackenby, O. Hungnes, B. Lina, S. van-der-Werf, B. Schweiger, M. Opp, J. Paget, J. van-de-Kassteele, A. Hay, and M. Zambon. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
27. Mishin, V. P., F. G. Hayden, and L. V. Gubareva. 2005. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49:4515-4520.
28. Moscona, A. 2008. Medical management of influenza infection. Annu. Rev. Med. 59:397-413.
29. Mungall, B. A., X. Xu, and A. Klimov. 2003. Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 47:1141-1144.
30. Okomo-Adhiambo, M., H. T. Nguyen, K. Sleeman, T. G. Sheu, V. M. Deyde, R. J. Garten, X. Xu, M. W. Shaw, A. I. Klimov, and L. V. Gubareva. 2010. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 85:381-388.
31. Pinto, L. H., and R. A. Lamb. 2006. Influenza virus proton channels. Photochem. Photobiol. Sci. 5:629-632.
32. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha- D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
33. Schirmer, P., and M. Holodniy. 2009. Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin. Drug Saf. 8:357-371.
34. Sheu, T. G., V. M. Deyde, M. Okomo-Adhiambo, R. J. Garten, X. Xu, R. A. Bright, E. N. Butler, T. R. Wallis, A. I. Klimov, and L. V. Gubareva. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
35. Tisdale, M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
36. Varghese, J. N., W. G. Laver, and P. M. Colman. 1983. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303:35-40.
37. Weinstock, D. M., L. V. Gubareva, and G. Zuccotti. 2003. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348:867-868.
38. Wetherall, N. T., T. Trivedi, J. Zeller, C. Hodges-Savola, J. L. McKimm-Breschkin, M. Zambon, and F. G. Hayden. 2003. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41:742-750.
39. Yen, H.-L., L. M. Herlocher, E. Hoffmann, M. N. Matrosovich, A. S. Monto, R. G. Webster, and E. A. Govorkova. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.